Neuberger Berman Group
ANIP icon

Neuberger Berman Group’s ANI Pharmaceuticals ANIP Stock Holding History

Neuberger Berman Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$802K Buy
9,694
+659
+7% +$52.9K ﹤0.01% 1601
2026
Q1 		$695K Sell
9,035
-6,215
-41% -$485K ﹤0.01% 1539
2025
Q4 		$1.2M Buy
15,250
+8,181
+116% +$708K ﹤0.01% 1344
2025
Q3 		$648K Buy
7,069
+1,146
+19% +$93.4K ﹤0.01% 1521
2025
Q2 		$386K Buy
5,923
+597
+11% +$38.9K ﹤0.01% 1661
2025
Q1 		$357K Sell
5,326
-138
-3% -$8.24K ﹤0.01% 1645
2024
Q4 		$302K Sell
5,464
-85
-2% -$4.88K ﹤0.01% 1667
2024
Q3 		$331K Buy
5,549
+24
+0.4% +$1.46K ﹤0.01% 1649
2024
Q2 		$352K Buy
+5,525
New +$359K ﹤0.01% 1599

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group's ANIP Position: Q2 2026 in Review

Neuberger Berman Group increased its ANI Pharmaceuticals (ANIP) stake by 7.3% in Q2 2026, buying an estimated $52.9K and bringing the position to 9,694 shares worth $802K. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

Neuberger Berman Group first reported a position in ANIP in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.2M in Q4 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Neuberger Berman Group held 9,694 shares of ANI Pharmaceuticals worth $802K as of Q2 2026.
  • Neuberger Berman Group bought 659 ANI Pharmaceuticals shares in Q2 2026, an estimated $52.9K.
  • ANI Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1601 holding.
  • Neuberger Berman Group first reported a position in ANI Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Neuberger Berman Group's ANI Pharmaceuticals position peaked at $1.2M in Q4 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.